LILRB4 expression in chronic myelomonocytic leukemia and myelodysplastic syndrome based on response to hypomethylating agents
暂无分享,去创建一个
K. Do | H. Kantarjian | G. Garcia-Manero | R. Kanagal-Shamanna | Hui Yang | K. Soltysiak | C. Class | Yue Wei | K. Sasaki | G. Montalban-Bravo | I. Ganan-Gomez | K. Naqvi | K. Chien | Caleb A. Class
[1] A. Goldberg,et al. Immune Checkpoint Inhibitors in Acute Myeloid Leukemia: Novel Combinations and Therapeutic Targets , 2019, Current Oncology Reports.
[2] J. Bewersdorf,et al. Immunotherapy in acute myeloid leukemia and myelodysplastic syndromes: The dawn of a new era? , 2019, Blood reviews.
[3] C. Zhang,et al. A Novel Anti-LILRB4 CAR-T Cell for the Treatment of Monocytic AML. , 2018, Molecular therapy : the journal of the American Society of Gene Therapy.
[4] Benjamin P. C. Chen,et al. LILRB4 signaling in leukemia cells mediates T cell suppression and tumor infiltration , 2018, Nature.
[5] E. Warren,et al. A Multi-center Phase I Trial of Ipilimumab in Patients with Myelodysplastic Syndromes following Hypomethylating Agent Failure , 2018, Clinical Cancer Research.
[6] J. Kline,et al. Mechanisms of Immune Tolerance in Leukemia and Lymphoma. , 2017, Trends in immunology.
[7] P. Sharma,et al. Phase IB/II Study of Nivolumab in Combination with Azacytidine (AZA) in Patients (pts) with Relapsed Acute Myeloid Leukemia (AML) , 2016 .
[8] Mario Cazzola,et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. , 2016, Blood.
[9] C. Zhang,et al. Inhibitory leukocyte immunoglobulin-like receptors: Immune checkpoint proteins and tumor sustaining factors , 2015, Cell cycle.
[10] H. Groen,et al. Immunoglobulin-like transcript 3 is expressed by myeloid-derived suppressor cells and correlates with survival in patients with non-small cell lung cancer , 2015, Oncoimmunology.
[11] W. Huber,et al. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2 , 2014, Genome Biology.
[12] Cole Trapnell,et al. TopHat2: accurate alignment of transcriptomes in the presence of insertions, deletions and gene fusions , 2013, Genome Biology.
[13] V. D’Agati,et al. Soluble Ig-Like Transcript 3 Inhibits Tumor Allograft Rejection in Humanized SCID Mice and T Cell Responses in Cancer Patients1 , 2007, The Journal of Immunology.
[14] B. Cheson,et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. , 2006, Blood.
[15] S. Kim-Schulze,et al. Recombinant Ig-Like Transcript 3-Fc Modulates T Cell Responses via Induction of Th Anergy and Differentiation of CD8+ T Suppressor Cells1 , 2006, The Journal of Immunology.
[16] Pablo Tamayo,et al. Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[17] Manfred Brockhaus,et al. A Novel Inhibitory Receptor (ILT3) Expressed on Monocytes, Macrophages, and Dendritic Cells Involved in Antigen Processing , 1997, The Journal of experimental medicine.
[18] T Hamblin,et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. , 1997, Blood.
[19] N. Rouas-Freiss,et al. HLA-G: An Immune Checkpoint Molecule. , 2015, Advances in immunology.
[20] G. Serban,et al. Expression of immune inhibitory receptor ILT3 in acute myeloid leukemia with monocytic differentiation , 2013, Cytometry. Part B, Clinical cytometry.